FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065851152> ?p ?o ?g. }

• W2065851152 endingPage "954" @default.
• W2065851152 startingPage "952" @default.
• W2065851152 abstract "Brief Reports15 December 1991Effects of Long-term Sulindac Therapy on Colonic PolyposisJoaquim Rigau, MD, Josep M. Piqué, MD, Elisa Rubio, MD, Ramón Planas, MD, Josep M. Tarrech, MD, Josep M. Bordas, MDJoaquim Rigau, MDSearch for more papers by this author, Josep M. Piqué, MDSearch for more papers by this author, Elisa Rubio, MDSearch for more papers by this author, Ramón Planas, MDSearch for more papers by this author, Josep M. Tarrech, MDSearch for more papers by this author, Josep M. Bordas, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-115-12-952 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSulindac treatment has been reported to induce marked reductions in the number and size of adenomatous polyps in the rectal segment after subtotal colectomy (1). These findings were not conclusive, however, because spontaneous remission of rectal adenomas after colectomy and ileorectal anastomosis has been described in patients with familial polyposis (2). Gonzaga and co-workers (3) and Wadell and associates (4) have described patients for whom sulindac treatment has led to a decrease in diffuse adenomatous polyps in intact colons. We report our experience with seven patients having diffuse colonic polyposis treated with sulindac. Endogenous prostaglandin generation in the colonic mucosa...References1. WaddellLoughry WR. Sulindac for polyposis of the colon. J Surg Oncol. 1983;24:83-7. CrossrefMedlineGoogle Scholar2. NichollsSpringallGallagher RRP. Regression of rectal adenomas after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Br Med J. 1988;296:1707-8. CrossrefMedlineGoogle Scholar3. GonzagaLimaCarneiroMacielAmarante RFSJJM. Sulindac treatment for familial polyposis coli [Letter]. Lancet. 1985;1:751. CrossrefMedlineGoogle Scholar4. WaddellGanserCeriseLoughry WGER. Sulindac for polyposis of the colon. Am J Surg. 1989;157:175-9. CrossrefMedlineGoogle Scholar5. SaperasPérez AyusoPocaBordasGayaPiqué EREJJJ. Increased gastric PGE2 biosynthesis in cirrhotic patients with gastric vascular ectasia. Am J Gastroenterol. 1990;85:138-44. MedlineGoogle Scholar6. MoorghenInceFinneySunterAppletonWatson MPKJDA. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol. 1988;156:341-7. CrossrefMedlineGoogle Scholar7. StrykerWolffCulpLibbeIlstrupMacCarty SBCSDR. Natural history of untreated colonic polyps. Gastroenterology. 1987;93:1009-13. CrossrefMedlineGoogle Scholar8. CappellForde MK. Spatial clustering of multiple hyperplastic, adenomatous, and malignant colonic polyps in individual patients. Dis Col Rectum. 1989;32:641-52. CrossrefMedlineGoogle Scholar9. BengoecheaMartinez-PeñuelaLarrinagaValerdiBorda OJBJF. Hyperplastic polyposis of the colorectum and adenocarcinoma in a 24-year-old man. Am J Surg Pathol. 1987;11:323-7. CrossrefMedlineGoogle Scholar10. NicholsonNeoptolemosClaytonTalbotBell MJHIP. Increased cell membrane arachidonic acid in experimental colorectal tumors. Gut. 1991;32:413-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From the Hospital General de Granollers; the Hospital Clínic de Barcelona: and the Hospital Germans Trias i Pujol de Badalona, Barcelona, Spain. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByNonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancerPIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugsColorectal Carcinoma: A General Overview and Future Perspectives in Colorectal CancerClinical Effects of NSAIDs and COXIBs in Colon Cancer PreventionSulindacMalignant Tumors of the ColonEicosanoid pathway in colorectal cancer: Recent updatesThe Role of Inflammation in Colon CancereRapa Restores a Normal Life Span in a FAP Mouse ModelSulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin SignalingChemoprevention in familial adenomatous polyposisMolecular Alterations Associated with Sulindac-Resistant Colon Tumors in ApcMin/+ MiceCyclo-oxygenase-2 expression in photon-radiated and non-radiated uveal melanomasThe Safety and Efficacy of Celecoxib in Children With Familial Adenomatous PolyposisPrimary Prevention of Colorectal CancerNSAIDs: Old Drugs Reveal New Anticancer TargetsChemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for useNON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)Gastroduodenal involvement in patients with familial adenomatous polyposis. Prospective study of the nature and evolution of polyps: evaluation of the treatment and surveillance methods appliedAspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized TrialsPOLYPOSIS SYNDROMESCiclooxigenasa 2 y cáncer colorrectal: implicaciones terapéuticasNonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task ForceAlaa Rostom, MD, MSc, Catherine Dubé, MD, MSc, Gabriela Lewin, MD, Alexander Tsertsvadze, MD, MSc, Nicholas Barrowman, PhD, Catherine Code, MD, Margaret Sampson, MLIS, and David Moher, PhD, for the U.S. Preventive Services Task ForceCelecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130CasDepressed-Type Early Invasive Colon Cancer in a Patient Treated with Cyclooxygenase-2 InhibitorCyclooxygenase 2 Expression in Colorectal Cancer with DNA Mismatch Repair DeficiencySulindacEffect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposisLipid peroxidation and prostaglandins in colorectal cancerActivities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancerChoice of prophylactic surgery for the large bowel component of familial adenomatous polyposisRandomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposisCOX-2: A Molecular Target for Colorectal Cancer PreventionCOX-2 inhibition as a tool to treat and prevent colorectal cancerTreatment of CarcinogenesisSelect Cyclic Nucleotide Phosphodiesterase Inhibitors in Colon Tumor Chemoprevention and ChemotherapyEffects of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancerRole of COX-2 Inhibitors in Cancer TherapyCyclooxygenase‐2 and 5‐lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapyUse of NSAIDs for the Chemoprevention of Colorectal CancerThe cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrenceNon-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer preventionModifiable risk factors for colon cancerReducing the Risk of Colorectal Cancer by Intervening in the Process of CarcinogenesisScreening for Colon Cancer and Evaluation of Chemoprevention with CoxibsCOX-2, prostanoids and colon cancerRationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitorsNonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemopreventionThe non-inherited gastrointestinal polyposis syndromesNSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of actionChemoprevention of colorectal cancer by aspirin: A cost-effectiveness analysisCelecoxib as Adjunctive Therapy for Treatment of Colorectal CancerRelationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposisUnderstanding the Interaction Between Environmental Exposures and Molecular Events in Colorectal CarcinogenesisChemoprevention of Colorectal CancerPRIMARY CANCER PREVENTION TRIALSThe Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisChemoprevention of Colorectal CancerLong-term treatment with sulindac in familial adenomatous polyposis: Is there an actual efficacy in prevention of rectal cancer?Treatment and survival study in the C57BL/6J-APCMin/+ (Min) mouse with R-flurbiprofenChemoprevention in hereditary colorectal cancer syndromesTermination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in ratsChemoprevention in hereditary colorectal cancer syndromesSulindac Inhibits Activation of the NF-κB PathwayThe prevention of colorectal cancer by aspirin useColorectal cancerSulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous PolyposisSulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the ratRectal cancer after sulindac therapy for a sporadic adenomatous colonic polypThe advent of highly selective inhibitors of cyclooxygenase—a reviewNon-Steroidal Anti-Inflammatory Drugs and the Chemoprevention of Gastrointestinal CancersClinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposisCHEMOPREVENTION FOR COLORECTAL CARCINOMAColorectal Cancer and Nonsteroidal Anti-inflammatory DrugsCyclo-oxygenase and Colon Cancer: Clues to the Aspirin Effect?NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, EICOSANOIDS, AND COLORECTAL CANCER PREVENTIONCyclooxygenase, NSAIDs, and colorectal cancerEffect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposisInflammation and metastasesLong-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasiaAntiproliferative Effects of the Enantiomers of FlurbiprofenNSAID USE AND DECREASED RISK OF GASTROINTESTINAL CANCERSNSAID-INDUCED POLYP REGRESSION IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTSSulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study.Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenograftsClinical development plan: Sulindac sulfoneNichtsteroidale Antirheumatika in der Ätiopathogenese kolorektaler Tumore — nur eine Hypothese?Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLCNonhormonal drugs and cancer.COLON CANCER SURVEILLANCEComplete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatmentProstaglandin synthesis in human cancer cells: Influence of fatty acids and butyrateEicosanoids and the gastrointestinal tractThe role of nonsteroidal anti-inflammatory drugs in colorectal cancer preventionEffect of sulindac on sporadic colonic polypsNonsteroidal anti-inflammatory drug use and sporadic colorectal adenomasRectal cancer after prolonged sulindac chemoprevention. A case reportDo NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?Aspirin, NSAIDs, and digestive tract cancersSulindac and polyp regressionNonsteroidal antiinflammatory drugs and human cancer. Report of an interdisciplinary research workshopNonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer at what cost?Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomasAdenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapyNon-steroidal anti-inflammatory drugs and tumor progression: inhibition of fibroblast hyaluronic acid production by indomethacin and mefenamic acidSimilarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention.Aspirin and the prevention of colorectal cancer: A review of the evidenceColon cancer detection: An algorithm using endoscopy and barium enemaTHE EFFECT OF MISOPROSTOL ON COLON CANCERClinical development plan: SulindacThe effect of sulindac on colon polyps: Circumvention of a transformed phenotype—A hypothesisCyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapiesMolecular Diagnosis of Familial Adenomatous PolyposisPancreatico-duodenectomy for cancer and precancer in familial adenomatous polyposisTreatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous PolyposisPräkanzerosen und Risikogruppen der kolorektalen KarzinomeClinical trials with anticoagulant and antiplatelet therapiesThe adenoma-adenocarcinoma sequence in the large bowel: Variations on a themePiroxicam and other cyclooxygenase inhibitors: Potential for cancer chemopreventionGardner Syndrome 15 December 1991Volume 115, Issue 12Page: 952-954KeywordsAdenomasColectomyColonGastroenterology and hepatologyMucous membranesProstaglandinSurgery Issue Published: 15 December 1991 PDF DownloadLoading ..." @default.
• W2065851152 created "2016-06-24" @default.
• W2065851152 creator A5009052655 @default.
• W2065851152 creator A5025082765 @default.
• W2065851152 creator A5030635582 @default.
• W2065851152 creator A5037338741 @default.
• W2065851152 creator A5063343695 @default.
• W2065851152 creator A5065696284 @default.
• W2065851152 date "1991-12-15" @default.
• W2065851152 modified "2023-09-25" @default.
• W2065851152 title "Effects of Long-term Sulindac Therapy on Colonic Polyposis" @default.
• W2065851152 cites W1562197307 @default.
• W2065851152 cites W1995568029 @default.
• W2065851152 cites W1995978700 @default.
• W2065851152 cites W1999104272 @default.
• W2065851152 cites W2004720788 @default.
• W2065851152 cites W2038453831 @default.
• W2065851152 cites W2057252291 @default.
• W2065851152 cites W2058218433 @default.
• W2065851152 cites W2069613201 @default.
• W2065851152 doi "https://doi.org/10.7326/0003-4819-115-12-952" @default.
• W2065851152 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1659272" @default.
• W2065851152 hasPublicationYear "1991" @default.
• W2065851152 type Work @default.
• W2065851152 sameAs 2065851152 @default.
• W2065851152 citedByCount "189" @default.
• W2065851152 countsByYear W20658511522012 @default.
• W2065851152 countsByYear W20658511522013 @default.
• W2065851152 countsByYear W20658511522014 @default.
• W2065851152 countsByYear W20658511522015 @default.
• W2065851152 countsByYear W20658511522016 @default.
• W2065851152 countsByYear W20658511522017 @default.
• W2065851152 countsByYear W20658511522019 @default.
• W2065851152 countsByYear W20658511522020 @default.
• W2065851152 countsByYear W20658511522021 @default.
• W2065851152 countsByYear W20658511522022 @default.
• W2065851152 countsByYear W20658511522023 @default.
• W2065851152 crossrefType "journal-article" @default.
• W2065851152 hasAuthorship W2065851152A5009052655 @default.
• W2065851152 hasAuthorship W2065851152A5025082765 @default.
• W2065851152 hasAuthorship W2065851152A5030635582 @default.
• W2065851152 hasAuthorship W2065851152A5037338741 @default.
• W2065851152 hasAuthorship W2065851152A5063343695 @default.
• W2065851152 hasAuthorship W2065851152A5065696284 @default.
• W2065851152 hasConcept C121332964 @default.
• W2065851152 hasConcept C126322002 @default.
• W2065851152 hasConcept C177713679 @default.
• W2065851152 hasConcept C2776241388 @default.
• W2065851152 hasConcept C2778484676 @default.
• W2065851152 hasConcept C61797465 @default.
• W2065851152 hasConcept C62520636 @default.
• W2065851152 hasConcept C71924100 @default.
• W2065851152 hasConcept C90924648 @default.
• W2065851152 hasConceptScore W2065851152C121332964 @default.
• W2065851152 hasConceptScore W2065851152C126322002 @default.
• W2065851152 hasConceptScore W2065851152C177713679 @default.
• W2065851152 hasConceptScore W2065851152C2776241388 @default.
• W2065851152 hasConceptScore W2065851152C2778484676 @default.
• W2065851152 hasConceptScore W2065851152C61797465 @default.
• W2065851152 hasConceptScore W2065851152C62520636 @default.
• W2065851152 hasConceptScore W2065851152C71924100 @default.
• W2065851152 hasConceptScore W2065851152C90924648 @default.
• W2065851152 hasIssue "12" @default.
• W2065851152 hasLocation W20658511521 @default.
• W2065851152 hasLocation W20658511522 @default.
• W2065851152 hasOpenAccess W2065851152 @default.
• W2065851152 hasPrimaryLocation W20658511521 @default.
• W2065851152 hasRelatedWork W1995568029 @default.
• W2065851152 hasRelatedWork W2030024070 @default.
• W2065851152 hasRelatedWork W2035613882 @default.
• W2065851152 hasRelatedWork W2036733130 @default.
• W2065851152 hasRelatedWork W2038443607 @default.
• W2065851152 hasRelatedWork W2625961828 @default.
• W2065851152 hasRelatedWork W2748952813 @default.
• W2065851152 hasRelatedWork W2899084033 @default.
• W2065851152 hasRelatedWork W3031052312 @default.
• W2065851152 hasRelatedWork W4385636856 @default.
• W2065851152 hasVolume "115" @default.
• W2065851152 isParatext "false" @default.
• W2065851152 isRetracted "false" @default.
• W2065851152 magId "2065851152" @default.
• W2065851152 workType "article" @default.